Skip to main content
SpringerLink
Log in

Systemic Implications of Melanoma

  • Chapter
  • First Online:
Dermato-Oncology Study Guide

Abstract

Although the most common presentation of cutaneous malignant melanoma is in the form of a localized primary tumor of the skin, systemic involvement (regional and/or distant metastases) is apparent at diagnosis in approximately 15% of cases [1]. It is important for the practicing clinician to have a thorough understanding of the epidemiology, pathophysiology, and treatment of melanoma, as endorsement of prevention strategies, proper screening regimens, and appropriate treatment of early stage disease all play a role in preventing the development of advanced disease. For patients who do present with systemic involvement, recent advances in molecular biology and immunology have led to novel therapeutic targets and resultant life-prolonging treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AAD:

American Academy of Dermatology

ASCO:

American Society of Clinical Oncology

cSCC:

Cutaneous squamous cell carcinoma

CT:

Computed tomography

FAMM:

Familial atypical multiple mole

FISH:

Fluorescent in situ hybridization

IBD:

Inflammatory bowel disease

KA:

Keratoacanthoma

OR:

Odds Ratio

PET:

Positron emission tomography

PUVA:

Psoralen plus ultraviolet A

RR:

Relative Risk

SDDI:

Sequential digital dermoscopy imaging

SPF:

Sun protection factor

SSO:

Society of Surgical Oncology

UV:

Ultraviolet

UVB:

Ultraviolet B

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  2. American Cancer Society. Key statistics for melanoma skin cancer 2018. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html.

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    Article  PubMed  Google Scholar 

  4. DS R. NYU melanoma cooperative group statistical report. 2018.

    Google Scholar 

  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  6. Svoboda RM, Glazer AM, Farberg AS, Cowdrey MCE, Rigel DS. Melanoma reporting practices of United States dermatologists. Dermatol Surg. 2018;44(11):1391–5.

    Article  PubMed  CAS  Google Scholar 

  7. Cartee TV, Kini SP, Chen SC. Melanoma reporting to central cancer registries by US dermatologists: an analysis of the persistent knowledge and practice gap. J Am Acad Dermatol. 2011;65(5 Suppl 1):S124–32.

    PubMed  Google Scholar 

  8. Heuring E, Chen SC. Melanoma underreporting among US dermatopathologists: a pilot study. J Cutan Pathol. 2018;45(7):550–1.

    Article  PubMed  Google Scholar 

  9. Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953-2008—are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385–400.

    Article  PubMed  CAS  Google Scholar 

  10. Apalla Z, Nashan D, Weller RB, Castellsague X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther. 2017;7(Suppl 1):5–19.

    Article  Google Scholar 

  11. Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989–2009. J Natl Cancer Inst. 2016;108(1):djv294.

    Article  PubMed  Google Scholar 

  12. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–800.

    Article  PubMed  Google Scholar 

  13. National Cancer Institute. Surveillance, epidemiology, and end results program 2017. https://seer.cancer.gov/statfacts/html/melan.html.

  14. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997;73(2):198–203.

    Article  PubMed  CAS  Google Scholar 

  15. Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol. 2014;70(5):847–57.e1–18.

    Article  PubMed  Google Scholar 

  16. American Cancer Society. Cancer facts and figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.

  17. Skin Cancer Foundation. Skin cancer facts & statistics 2018. https://www.skincancer.org/skin-cancer-information/skin-cancer-facts.

  18. Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of melanoma. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy. Brisbane: Codon Publications The Authors; 2017.

    Google Scholar 

  19. Yuan TA, Meyskens F, Liu-Smith F. A cancer registry-based analysis on the non-white populations reveals a critical role of the female sex in early-onset melanoma. Cancer Causes Control. 2018;29:405–15.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Feng Z, Zhang Z, Wu XC. Lifetime risks of cutaneous melanoma by histological subtype and race/ethnicity in the United States. J Louisiana State Med Soc. 2013;165(4):201–8.

    Google Scholar 

  21. Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748–62.

    Article  PubMed  Google Scholar 

  22. Nabil R, Plasmeijer E, van Doorn R, Bergman W, Kukutsch NA. Unscheduled visits of patients with familial melanoma to a pigmented lesion clinic: evaluation of patients’ characteristics and suspicious lesions. Acta Derm Venereol. 2018;98:667–70.

    Article  PubMed  Google Scholar 

  23. Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016;74(3):395–407; quiz 8–10.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28–44.

    Article  PubMed  Google Scholar 

  25. Geller AC, Mayer JE, Sober AJ, Miller DR, Argenziano G, Johnson TM, et al. Total nevi, atypical nevi, and melanoma thickness: an analysis of 566 patients at 2 US centers. JAMA Dermatol. 2016;152(4):413–8.

    Article  PubMed  Google Scholar 

  26. Singh S, Nagpal SJ, Murad MH, Yadav S, Kane SV, Pardi DS, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(2):210–8.

    Article  PubMed  Google Scholar 

  27. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.

    Article  PubMed  CAS  Google Scholar 

  29. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant. 1998;2(1):56–63.

    PubMed  CAS  Google Scholar 

  30. Ali FR, Lear JT. Melanoma in organ transplant recipients: incidence, outcomes and management considerations. J Skin Cancer. 2012;2012:404615.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Maiorino A, De Simone C, Perino F, Caldarola G, Peris K. Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. J Dermatolog Treat. 2016;27(5):443–7.

    Article  PubMed  Google Scholar 

  32. Disse M, Reich H, Lee PK, Schram SS. A review of the association between Parkinson disease and malignant melanoma. Dermatol Surg. 2016;42(2):141–6.

    Article  PubMed  CAS  Google Scholar 

  33. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63.

    Article  PubMed  CAS  Google Scholar 

  34. Olsen CM, Wilson LF, Green AC, Biswas N, Loyalka J, Whiteman DC. How many melanomas might be prevented if more people applied sunscreen regularly? Br J Dermatol. 2018;178(1):140–7.

    Article  PubMed  CAS  Google Scholar 

  35. Williams JD, Maitra P, Atillasoy E, Wu MM, Farberg AS, Rigel DS. SPF 100+ sunscreen is more protective against sunburn than SPF 50+ in actual use: results of a randomized, double-blind, split-face, natural sunlight exposure clinical trial. J Am Acad Dermatol. 2018;78(5):902–10.e2.

    Article  PubMed  CAS  Google Scholar 

  36. Koh HK, Miller DR, Geller AC, Clapp RW, Mercer MB, Lew RA. Who discovers melanoma? Patterns from a population-based survey. J Am Acad Dermatol. 1992;26(6):914–9.

    Article  PubMed  CAS  Google Scholar 

  37. Brady MS, Oliveria SA, Christos PJ, Berwick M, Coit DG, Katz J, et al. Patterns of detection in patients with cutaneous melanoma. Cancer. 2000;89(2):342–7.

    Article  PubMed  CAS  Google Scholar 

  38. Rigel DS, Friedman RJ. The rationale of the ABCDs of early melanoma. J Am Acad Dermatol. 1993;29(6):1060–1.

    Article  PubMed  CAS  Google Scholar 

  39. AAD statement on USPSTF recommendation on skin cance screening [press release]. 2016.

    Google Scholar 

  40. Dermatology AAo. How to perform a total body skin exam 2015.

    Google Scholar 

  41. Tsao H, Pehamberger H, Sober A. Precursor lesions and markers of increased risk for melanoma. In: Cutaneous melanoma. St Louis: Quality Medical Publishing Inc.; 1998. p. 65–79.

    Google Scholar 

  42. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011;65(5):1032–47.

    Article  PubMed  Google Scholar 

  43. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, et al. Melanoma. J Natl Comp Cancer Netw. 2009;7(3):250–75.

    Article  CAS  Google Scholar 

  44. Farberg AS, Rigel DS. A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma. J Am Acad Dermatol. 2016;75(6):1193–7.e1.

    Article  PubMed  Google Scholar 

  45. Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P, Kelly JW. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol. 2010;146(3):234–9.

    Article  PubMed  Google Scholar 

  46. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159–65.

    Article  PubMed  CAS  Google Scholar 

  47. Winkelmann RR, Farberg AS, Glazer AM, Cockerell CJ, Sober AJ, Siegel DM, et al. Integrating skin cancer-related technologies into clinical practice. Dermatol Clin. 2017;35(4):565–76.

    Article  PubMed  CAS  Google Scholar 

  48. Xiong YQ, Mo Y, Wen YQ, Cheng MJ, Huo ST, Chen XJ, et al. Optical coherence tomography for the diagnosis of malignant skin tumors: a meta-analysis. J Biomed Opt. 2018;23(2):1–10.

    Article  PubMed  Google Scholar 

  49. Ferris LK, Jansen B, Ho J, Busam KJ, Gross K, Hansen DD, et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol. 2017;153(7):675–80.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Reimann JDR, Salim S, Velazquez EF, Wang L, Williams KM, Flejter WL, et al. Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms. Mod Pathol. 2018;31(11):1733–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Ko JS, Matharoo-Ball B, Billings SD, Thomson BJ, Tang JY, Sarin KY, et al. Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes. Cancer Epidemiol Biomark Prev. 2017;26(7):1107–13.

    Article  Google Scholar 

  52. Gershenwald JE, Scloyler RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:2105–10.

    Article  PubMed  Google Scholar 

  53. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.

    Article  PubMed  Google Scholar 

  56. Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(4):399–413.

    Article  PubMed  Google Scholar 

  57. Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72(5):780–5.e3.

    Article  PubMed  CAS  Google Scholar 

  58. Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–83.

    Article  PubMed  CAS  Google Scholar 

  59. Hsueh EC, DeBloom JR, Lee J, Sussman JJ, Covington KR, Middlebrook B, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017;10(1):152.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Hsueh EC, Schwartz TL, Lizalek JM, Hunborg PS, Hurley MY, Hinyard LJ. Prospective validation of gene expression profiling in primary cutaneous melanoma. American Society of Clinical Oncology; 2016.

    Google Scholar 

  61. Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18(1):130.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on cancer individualized melanoma patient outcome prediction tool with a 31-gene expression profile-based classification. J Am Acad Dermatol. 2017;76(5):818–25.e3.

    Article  PubMed  Google Scholar 

  63. Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. J Am Acad Dermatol. 2018;78(1):40–6.e7.

    Article  PubMed  Google Scholar 

  64. Deutsch GB, Kirchoff DD, Faries MB. Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am. 2015;24(2):279–98.

    Article  PubMed  Google Scholar 

  65. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol. 2012;66(3):438–44.

    Article  PubMed  Google Scholar 

  66. Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol. 2016;17(2):184–92.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Wilson MA, Schuchter LM. Chemotherapy for melanoma. Cancer Treat Res. 2016;167:209–29.

    Article  PubMed  Google Scholar 

  68. Perier-Muzet M, Gatt E, Peron J, Falandry C, Amini-Adle M, Thomas L, et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol. 2018;154(1):82–7.

    Article  PubMed  Google Scholar 

  69. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

    Article  PubMed  CAS  Google Scholar 

  70. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553(7688):347–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, NY). 2018;359(6371):91–7.

    Article  CAS  Google Scholar 

  72. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science (New York, NY). 2018;359(6371):104–8.

    Article  CAS  Google Scholar 

  73. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–92.

    Article  CAS  PubMed  Google Scholar 

  75. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol. 1999;77(1):1–10.

    Article  PubMed  CAS  Google Scholar 

  76. Lens M, Testori A, Ferucci PF. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma. Curr Top Med Chem. 2012;12(1):61–6.

    Article  PubMed  CAS  Google Scholar 

  77. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.

    Article  PubMed  CAS  Google Scholar 

  78. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer center. J Clin Oncol. 2015;33(28):3193–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell. 2015;27(4):437–8.

    Article  PubMed  CAS  Google Scholar 

  80. Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391–8.

    Article  PubMed  CAS  Google Scholar 

  81. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. McCain J. The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma. P&T. 2013;38(2):96–108.

    Google Scholar 

  83. Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res. 2006;4(10):779–92.

    Article  PubMed  CAS  Google Scholar 

  84. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776–84.

    Article  PubMed  CAS  Google Scholar 

  85. Tuma RS. Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug. J Natl Cancer Inst. 2011;103(3):170–1, 177.

    Article  PubMed  Google Scholar 

  86. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5):480–1.

    Article  PubMed  CAS  Google Scholar 

  91. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012;18(9):2502–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2012;380(9839):358–65.

    Article  CAS  Google Scholar 

  93. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013;49(6):1297–304.

    Article  PubMed  CAS  Google Scholar 

  94. Debarbieux S, Dalle S, Depaepe L, Poulalhon N, Balme B, Thomas L. Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy. Br J Dermatol. 2013;168(6):1230–5.

    Article  PubMed  CAS  Google Scholar 

  95. Yagerman S, Flores E, Busam K, Lacouture M, Marghoob AA. Overview photography and short-term mole monitoring in patients taking a BRAF inhibitor. JAMA Dermatol. 2014;150(9):1010–1.

    Article  PubMed  Google Scholar 

  96. Administration FaD. 2014.

    Google Scholar 

  97. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.

    Article  PubMed  CAS  Google Scholar 

  98. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 2015;386(9992):444–51.

    Article  CAS  Google Scholar 

  99. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Penn State Health, Hershey, PA, USA

    Ryan M. Svoboda

  2. Hough Graduate School of Business, University of Florida, Gainesville, FL, USA

    Giselle Prado

  3. Clinical Professor of Dermatology, New York University Medical Center, New York, NY, USA

    Darrell S. Rigel

Authors
  1. Ryan M. Svoboda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giselle Prado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darrell S. Rigel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Iowa Health Care, Iowa, IA, USA

    Vincent Liu

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Svoboda, R.M., Prado, G., Rigel, D.S. (2021). Systemic Implications of Melanoma. In: Liu, V. (eds) Dermato-Oncology Study Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-53437-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53437-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53436-3

  • Online ISBN: 978-3-030-53437-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation